UAE Medical Manuals Localisation

A Comprehensive Review of Clinical and Device Documentation Localisation for the UAE Healthcare Sector

(Company Logo)

Prepared By: Translation Services Team

Date:

Prepared For: UAE Healthcare & Medical Device Client Portfolio

Document Type: Project Portfolio Report

Document Control

Field	Detail
Document Title	UAE Medical Manuals Localisation: Project Portfolio Report
Document Type	Case Study / Project Portfolio Report
Prepared For	UAE Healthcare & Medical Device Client Portfolio
Classification	Client-Confidential Summary (Illustrative)
Version	Final

Abstract

This report documents a large-scale medical documentation localisation programme delivered for a healthcare device manufacturer distributing its products across hospitals, clinics and pharmacies in the United Arab Emirates. The scope of work covered device instructions for use, clinical reference manuals, patient safety information and dosage guidance, translated from English into Arabic in compliance with the documentation standards of the UAE Ministry of Health and Prevention (MOHAP). Given the direct patient-safety implications of medical documentation, the programme placed particular emphasis on clinical accuracy, terminology consistency and a verification methodology capable of catching even small errors before publication.

The chapters that follow describe the UAE regulatory framework governing medical device and pharmaceutical documentation, the clinical qualification standards applied to the localisation team, the terminology-management and back-translation methodology used to verify safety-critical content, the desktop-publishing process used to rebuild technical diagrams in Arabic, and the results achieved across the full manual set. The report closes with lessons learned and recommendations for future medical localisation engagements in the region.

Findings indicate that medical localisation carries a fundamentally different risk profile from general technical translation: an error in a dosage figure, a warning label or a contraindication can translate directly into patient harm. The verification framework documented in this report, built around independent clinical review and systematic back-translation of safety-critical passages, achieved a zero-defect outcome across all safety-relevant content and first-submission regulatory acceptance for the full manual set.

Table of Contents

Report Overview

This report is organised as a full project portfolio account rather than a brief summary, reflecting the scale and regulatory complexity of the underlying medical localisation programme. Readers seeking a quick reference may wish to begin with the Abstract, Chapter 15 (Results and Impact), and Appendix O (Summary of Key Success Factors), before returning to the full chapter sequence for methodological detail.

Chapter 1: Introduction to Medical Localisation in the UAE

Medical device and pharmaceutical companies operating in the UAE must ensure that every piece of documentation reaching a clinician or patient, from device instructions for use to dosage and safety information, is available in Arabic and meets the standards set by the UAE Ministry of Health and Prevention (MOHAP). Unlike general commercial or marketing localisation, medical documentation carries direct patient-safety consequences: a mistranslated dosage unit, an omitted contraindication, or an ambiguous warning can lead directly to patient harm rather than simply a poor customer experience.

This report documents a medical manuals localisation programme delivered for a healthcare device manufacturer distributing its product range across UAE hospitals, clinics and pharmacies. The engagement required localisation of device instructions for use, clinical reference manuals, patient information leaflets and dosage guidance, all of which needed to comply with MOHAP documentation standards before the client's products could be legally distributed in the UAE market.

1.1 Purpose and Scope of This Report

This report sets out the regulatory context governing medical documentation in the UAE, the clinical qualification standards applied to the localisation team, the terminology and verification methodology used to assure safety-critical accuracy, the desktop-publishing process used to localise technical diagrams, and the measurable outcomes achieved across the full manual set.

1.2 Why Medical Localisation Quality Matters

- Patient safety: dosage figures, contraindications and warnings must be translated with zero tolerance for ambiguity or error.
- Regulatory approval: MOHAP will not clear medical documentation for distribution unless it meets prescribed terminology and formatting standards.
- Legal liability: inaccurate medical translation exposes both the manufacturer and distributing healthcare providers to liability risk.
- Clinical usability: healthcare professionals and patients must be able to read and act on the documentation without needing to refer back to the English original.

> *“In medical localisation, a translation that is merely understandable is not good enough. It must be exact, because the reader may act on it without ever questioning it.”*

1.3 How This Report Is Organised

Chapters 2 and 3 set out the UAE regulatory landscape and the specific project scope; Chapters 4 through 9 describe the clinical team structure, terminology methodology, verification framework and desktop-publishing process; Chapters 10 through 15 cover case examples, challenges, solutions, client collaboration, timeline and measured results; and Chapters 16 through 23 draw out lessons learned, risk

management, data security, training and post-project review. A series of appendices provide reference material including an extended clinical terminology glossary and reusable procedural templates.

Chapter 2: The UAE Medical Regulatory Landscape

Medical device and pharmaceutical documentation distributed in the UAE falls under the oversight of the Ministry of Health and Prevention, which maintains registration and labelling requirements for products sold across the Emirates, alongside emirate-level health authorities such as the Dubai Health Authority (DHA) and the Department of Health Abu Dhabi (DOH), which apply their own additional requirements for products distributed within their respective jurisdictions.

2.1 MOHAP Registration and Labelling Requirements

Before a medical device or pharmaceutical product can be distributed in the UAE, its labelling, instructions for use and patient information must be submitted to MOHAP in Arabic, meeting prescribed terminology conventions for dosage units, warnings and contraindications. Any deviation from expected terminology can delay registration, directly affecting the manufacturer's ability to bring a product to market.

2.2 Emirate-Level Health Authority Requirements

Where the client's products were also distributed through hospitals and clinics regulated by the DHA or DOH, additional documentation conventions specific to those authorities needed to be layered on top of the baseline MOHAP requirements, requiring the localisation team to track more than one authority's expectations for portions of the manual set.

2.3 International Standards Referenced Locally

UAE medical documentation practice frequently references international standards, including International Organization for Standardization (ISO) conventions for medical device labelling symbols and pictograms, which the localisation team needed to recognise and preserve correctly alongside the Arabic text rather than translating symbol meanings inconsistently with their internationally recognised form.

Authority	Scope	Key Requirement
MOHAP	Federal product registration and labelling	Arabic labelling per MOHAP terminology standards
Dubai Health Authority (DHA)	Dubai-based healthcare provider distribution	DHA-specific documentation conventions
Department of Health Abu Dhabi (DOH)	Abu Dhabi-based healthcare provider distribution	DOH-specific documentation conventions
ISO Medical Device Standards	International labelling symbols and pictograms	Consistent, internationally recognised symbol use

Chapter 3: Project Scope and Objectives

The client is a healthcare device manufacturer with an established product range spanning diagnostic equipment, patient monitoring devices and a smaller range of consumables, distributed through hospital, clinic and pharmacy channels across the UAE. The engagement was initiated ahead of a coordinated regional product launch that required the client's full documentation library to be localised and MOHAP-cleared on a defined timeline.

3.1 Document Categories in Scope

- Device instructions for use (IFUs) for diagnostic and monitoring equipment.
- Clinical reference manuals for healthcare professional users.
- Patient information leaflets accompanying consumable products.
- Dosage and safety guidance for products with variable dosing parameters.
- Technical diagrams and labelling artwork containing embedded text.
- Packaging and labelling copy for MOHAP registration submission.

3.2 Project Objectives

Three objectives anchored the engagement. First, every dosage, warning and contraindication in the localised documentation needed to match its source with zero tolerance for ambiguity or omission. Second, terminology needed to remain consistent across the full manual set, since a device's instructions for use and its associated clinical reference manual frequently describe the same procedures and must use matching terminology to avoid confusing clinical readers. Third, every diagram and labelling artwork containing embedded text needed to be rebuilt in Arabic without disturbing the underlying technical accuracy of the original visual.

65	4	2
Manuals Localised	Device Product Lines	Health Authorities Coordinated

Chapter 4: Clinical Team Structure and Qualification

Given the patient-safety implications of the material, the project team was deliberately structured around clinical, not purely linguistic, competence.

4.1 Core Roles

Clinical Translators

Lead translators held a life-sciences, pharmacy or clinical background in addition to translation qualifications, and were assigned to document categories matching their clinical specialisation, such as diagnostic equipment or dosage-sensitive consumables, to ensure genuine subject-matter familiarity rather than generalist technical translation.

Independent Clinical Reviewers

A second clinically qualified linguist, independent of the original translator, reviewed every safety-critical section, including dosage figures, contraindications and warnings, before any document proceeded to the back-translation verification stage described in Chapter 6.

Desktop Publishing Specialists

Dedicated desktop-publishing specialists rebuilt technical diagrams and labelling artwork in Arabic, working closely with the clinical translation team to ensure that embedded text changes did not inadvertently alter the technical meaning of a diagram, such as a dosage chart or a device component label.

Terminology and Regulatory Coordinator

A dedicated coordinator maintained the master clinical terminology glossary, tracked MOHAP and emirate-level authority submission status for each document, and served as the primary liaison with the client's regulatory affairs team.

4.2 Qualification Standards Applied

- Life-sciences, pharmacy or clinical educational background for lead translators assigned to safety-critical content.
- Demonstrated prior experience with MOHAP-cleared medical documentation, verified through a clinical translation test set before onboarding.
- Native or near-native fluency in both source and target languages, combined with familiarity with UAE clinical terminology conventions.
- Independent clinical review by a linguist not involved in the original translation for all safety-critical passages.

Chapter 5: Terminology Management and Clinical Glossaries

Consistency of clinical terminology across a manufacturer's full documentation library is essential: a device's instructions for use, its clinical reference manual and its patient information leaflet frequently describe the same procedure or component, and any inconsistency between them creates confusion for the clinical reader at exactly the moment precision matters most.

5.1 Building the Master Clinical Glossary

The terminology coordinator built the master glossary by extracting recurring clinical terms from the client's existing English documentation and cross-referencing them against MOHAP-approved medical terminology and established Arabic clinical reference sources, selecting a single preferred rendering for each term and documenting the reasoning where more than one Arabic equivalent existed.

5.2 Sample Terminology Entries

Term	Definition
Contraindication	Rendered using the standard MOHAP-recognised clinical term, distinguished consistently from precaution.
Adverse Reaction	Rendered per established Arabic pharmacovigilance terminology, distinguished from side effect.
Dosage Interval	Numeric and unit terminology cross-checked against source figures at every review stage.
Contraindicated Population	Rendered to preserve the precise scope of excluded patient groups stated in the source.
Device Calibration	Rendered consistently across instructions for use and clinical reference manuals for the same device.
Sterile Field	Rendered per established Arabic clinical procedural terminology.

5.3 Maintaining the Glossary Through the Project

As with the legal terminology programme described elsewhere in this report series, any new clinical term encountered during translation was escalated to the terminology coordinator for review before being finalised and added to the glossary, preventing inconsistent ad hoc terminology choices across a manual set produced by more than one clinical translator.

Chapter 6: Translation Methodology and Back-Translation Verification

Given the safety-critical nature of the material, the project applied a verification methodology beyond standard translation review, centred on back-translation of all dosage and safety content.

6.1 The Translation and Verification Workflow

- Intake and classification: incoming manuals were logged and assigned to the clinical translator matching their device or product category.
- Terminology check: relevant glossary entries were reviewed before translation began.
- Draft translation: the clinical translator produced a full Arabic draft, flagging any source ambiguity for client clarification.
- Independent clinical review: a second clinically qualified linguist reviewed the draft in full, with particular attention to safety-critical passages.
- Back-translation: all dosage, warning and contraindication content was independently translated back into English by a third linguist who had not seen the original source, and compared against the original for any deviation in meaning.
- Desktop publishing and final formatting: diagrams and labelling artwork were rebuilt in Arabic and checked against the verified text.

6.2 Why Back-Translation Was Applied Selectively

Back-translating an entire manual would have been resource-intensive without proportionate benefit; the project instead applied back-translation specifically to dosage figures, warnings, contraindications and any passage flagged as safety-critical during the independent clinical review stage, concentrating verification effort where the consequences of error were most severe.

6.3 Resolving Back-Translation Discrepancies

Where a back-translation revealed even a subtle shift in meaning from the original English source, the passage was escalated for joint review by the original translator, the independent clinical reviewer and, where necessary, the client's own clinical affairs team, before the passage was finalised.

Chapter 7: Desktop Publishing and Diagram Localisation

A significant portion of the client's documentation relied on technical diagrams, dosage charts and device component labels with embedded text, all of which needed to be rebuilt in Arabic without compromising their technical accuracy or visual clarity.

7.1 Right-to-Left Layout Considerations

Arabic's right-to-left reading direction required more than a simple text swap within existing diagrams; numbered callouts, sequential step diagrams and directional arrows in the original English artwork often needed to be restructured so that the visual flow remained intuitive to an Arabic-reading clinician, rather than leaving a right-to-left text layer awkwardly embedded in a left-to-right visual structure.

7.2 Preserving Technical Accuracy in Rebuilt Diagrams

Desktop publishing specialists worked directly with the clinical translation team when rebuilding diagrams, ensuring that a relabelled dosage chart or device component diagram was checked against the verified Arabic text before finalisation, since a purely visual rebuild process risks introducing errors that a text-only review would not catch.

7.3 Symbol and Pictogram Consistency

Internationally recognised medical device symbols and pictograms were preserved in their standard form rather than translated, consistent with ISO conventions referenced by MOHAP, while accompanying explanatory text was localised in full.

Chapter 8: Quality Assurance and Regulatory Review Protocols

Quality assurance in this programme operated across four layers, reflecting the elevated risk profile of medical documentation relative to general technical or commercial translation.

8.1 Clinical Accuracy Review

The independent clinical reviewer compared every clause of safety-critical content against the source, checking not only vocabulary but clinical meaning, dosage units and any conditional language describing when a warning or contraindication applied.

8.2 Back-Translation Verification

As described in Chapter 6, dosage, warning and contraindication content underwent independent back-translation verification, adding a further layer of assurance beyond standard bilingual review.

8.3 Terminology Consistency Review

An automated consistency check compared clinical terminology across a device's full documentation set, flagging any deviation between, for example, an instructions-for-use document and its associated clinical reference manual.

8.4 Regulatory Formatting Compliance Review

A final review confirmed that each document met MOHAP and, where applicable, DHA or DOH formatting conventions before submission for registration clearance.

4	0	100%
Independent Review Layers	Safety Content Errors	MOHAP First-Pass Clearance

Chapter 9: Technology and Tools in Medical Localisation

Supporting technology played a role in maintaining consistency and traceability across a large, safety-critical manual set, without replacing the human clinical review that remained central to the project's quality framework.

9.1 Translation Memory and Clinical Terminology Databases

A translation memory system stored previously verified clinical phrases and standard warning language, allowing reuse of already-verified content across related documents rather than re-verifying identical safety language multiple times independently.

9.2 Diagram Version Control

Rebuilt diagrams were tracked through a version-control system linking each artwork file to the specific verified text version it reflected, preventing an outdated diagram from being paired with an updated text passage during final assembly.

9.3 Secure Handling of Regulatory Submission Material

Given the regulatory sensitivity of pre-clearance documentation, all files were handled through access-controlled, encrypted storage consistent with the client's regulatory affairs confidentiality requirements.

Chapter 10: Case Examples: Manual Types Localised

The following examples illustrate the range of documentation handled during the programme, generalised to protect commercially sensitive product details.

10.1 Diagnostic Equipment Instructions for Use

An instructions-for-use manual for a diagnostic monitoring device required careful handling of calibration procedures and error-code tables, where numeric precision and consistent terminology between the error-code table and the accompanying troubleshooting narrative were essential to clinical usability.

10.2 Dosage-Sensitive Consumable Patient Leaflet

A patient information leaflet for a dosage-variable consumable product underwent full back-translation verification of its dosage table, given the direct patient-safety consequences of any numeric or unit error in this specific document.

10.3 Clinical Reference Manual for Healthcare Professionals

A clinical reference manual intended for healthcare professional users required precise handling of procedural sequencing language, since an incorrectly ordered step in a clinical procedure carries direct patient-safety implications distinct from a simple readability issue.

10.4 Labelling Artwork for MOHAP Registration

Packaging labelling artwork submitted for MOHAP registration required exact alignment between the Arabic label text and the verified translation record, since any discrepancy between the two at submission stage risks delaying product registration.

Chapter 11: Challenges Encountered

The following were the most significant challenges encountered during the engagement, along with their immediate impact on the team's working process.

11.1 Numeric Precision Across Formats

Dosage figures appeared across multiple document formats, including narrative text, tables and diagram labels, for the same product, requiring the team to verify numeric consistency not only within a single document but across every document referencing the same dosage information.

11.2 Right-to-Left Diagram Restructuring at Scale

The volume of diagrams requiring right-to-left restructuring, described in Chapter 7, was higher than initially scoped, requiring additional desktop-publishing resourcing to maintain the project timeline without compromising review rigour.

11.3 Coordinating Two Health Authorities Simultaneously

Products distributed through both DHA-regulated and DOH-regulated channels required the team to track two sets of formatting expectations in parallel, in addition to the baseline MOHAP requirements applicable to all products.

11.4 Ambiguity in Source Clinical Language

In a small number of instances, the English source itself contained clinical language open to more than one reading; each instance was escalated to the client's clinical affairs team for clarification before finalisation, consistent with the escalation discipline described in Chapter 6.

Chapter 12: Solutions and Best Practices

Each challenge identified in the previous chapter was met with a specific process response, several of which became standing practice for the remainder of the engagement.

12.1 Cross-Document Numeric Consistency Checks

An automated numeric consistency check compared every instance of a dosage figure across a product's full documentation set, flagging any discrepancy for clinical review before final sign-off.

12.2 Dedicated Diagram Restructuring Resource

A dedicated desktop-publishing resource was added specifically for right-to-left diagram restructuring, working in a fixed pairing with one clinical translator to maintain consistent quality and pace across the diagram-heavy portion of the manual set.

12.3 Dual-Authority Formatting Templates

Separate formatting templates were developed for DHA- and DOH-bound documentation, layered on top of the baseline MOHAP template, allowing the team to apply the correct combination of requirements automatically based on a document's distribution channel.

12.4 Structured Clinical Query Log

A structured query log, shared with the client's clinical affairs team on a rolling basis, tracked every instance of source-language ambiguity, its resolution, and the resulting translation decision, creating an auditable record for regulatory purposes.

Chapter 13: Client Collaboration and Communication

Medical localisation of this scope depends on close, ongoing collaboration with the client's clinical and regulatory affairs teams, who hold the substantive clinical knowledge underlying the documentation.

13.1 Weekly Clinical Review Sessions

A standing weekly session between the project coordinator, the lead clinical translators and the client's clinical affairs team reviewed outstanding queries, back-translation findings and upcoming MOHAP submission deadlines.

13.2 Direct Clinical Escalation Channel

A direct escalation channel to the client's clinical affairs lead was established for any back-translation discrepancy requiring urgent clarification, avoiding delays that a standard email queue might otherwise introduce for safety-critical queries.

13.3 Post-Clearance Support

Following MOHAP clearance, the team remained available to support any authority queries raised during post-submission review, providing a rapid response channel to address clarification requests without delaying product launch timelines.

Chapter 14: Timeline and Delivery Management

The engagement was structured around three phases aligned to the client's regional product launch timeline.

14.1 Phase One: Terminology and Pilot Manual

The initial phase established the master clinical glossary and delivered a pilot manual to validate the full workflow, including back-translation verification and desktop publishing, before scaling to the full documentation library.

14.2 Phase Two: Full Manual Set Localisation

The second phase localised the remaining manual set across all four device product lines, applying the verification workflow validated in Phase One at full scale.

14.3 Phase Three: Regulatory Submission Support

The final phase supported MOHAP, DHA and DOH submission for all localised documentation, including responding to any authority queries raised during registration review.

Phase	Focus	Approximate Duration
Phase One	Terminology build and pilot manual	5 weeks
Phase Two	Full manual set localisation	14 weeks
Phase Three	Regulatory submission support	7 weeks

Chapter 15: Results and Impact

The programme delivered measurable outcomes across clinical accuracy, regulatory acceptance and launch timeline performance.

65	0	100%
Manuals Localised	Safety Content Errors	MOHAP First-Pass Clearance

15.1 Regulatory Acceptance

All localised documentation submitted during the engagement was cleared by MOHAP, and by the DHA and DOH where applicable, on first submission, without requests for revision.

15.2 Clinical Accuracy Outcome

The back-translation verification process applied to all safety-critical content identified and resolved every discrepancy before publication, resulting in zero safety-content errors across the full manual set at launch.

15.3 Launch Timeline Performance

The full documentation library was localised, verified and cleared in time to support the client's regional product launch on its original schedule, without the client needing to delay launch in any market due to documentation readiness.

Chapter 16: Lessons Learned and Recommendations

- Apply back-translation verification selectively but rigorously to all safety-critical content, rather than either skipping it or applying it uniformly regardless of risk level.
- Build the master clinical glossary before translation begins, referencing MOHAP-approved terminology from the outset.
- Treat right-to-left diagram restructuring as a distinct workstream requiring its own resourcing, not an afterthought to text translation.
- Maintain a structured clinical query log to keep every source-ambiguity resolution auditable for regulatory purposes.
- Coordinate multi-authority formatting requirements explicitly rather than assuming a single baseline template will satisfy every distribution channel.

16.1 Recommendations for Future Engagements

For future medical localisation programmes of similar scope, it is recommended that the pilot-manual validation approach used in Phase One be applied even earlier in the engagement lifecycle, allowing the full verification workflow to be stress-tested on a smaller document before committing to full-scale resourcing.

Chapter 17: Conclusion

This report has set out the structure, methodology and outcomes of a medical manuals localisation programme delivered for a healthcare device manufacturer operating across the UAE. The engagement demonstrated that reliable medical localisation outcomes depend on clinical, not purely linguistic, competence throughout the team, a verification framework built around independent clinical review and targeted back-translation, and close coordination with multiple health authority formatting requirements operating in parallel.

The zero-defect outcome achieved across all safety-critical content, combined with first-submission regulatory clearance across MOHAP, DHA and DOH channels, reflects the effectiveness of the methodology set out in this report and provides a reusable template for future medical localisation engagements of comparable scale in the UAE market.

Chapter 18: Risk Management in Medical Localisation Projects

Medical localisation carries a risk profile distinct from general technical translation, and the project maintained a dedicated risk register tracking safety, regulatory, schedule and confidentiality risk throughout the engagement.

18.1 Categories of Risk Identified

- Clinical risk: the possibility that a translated dosage figure or warning alters clinical meaning, addressed through independent review and back-translation.
- Regulatory risk: the possibility that documentation is rejected on formatting grounds by MOHAP, DHA or DOH, addressed through authority-specific templates.
- Schedule risk: the possibility that a launch deadline is missed, addressed through the phased delivery approach described in Chapter 14.
- Confidentiality risk: the possibility that pre-clearance product documentation is exposed, addressed through access-controlled, encrypted storage.

18.2 Risk Review Cadence

The risk register was reviewed at each weekly clinical review session, with any newly identified risk assigned an owner and target resolution date, ensuring risks were addressed while a document was still in the verification workflow.

18.3 Escalation Thresholds

Clear thresholds determined when a back-translation discrepancy or regulatory formatting issue required escalation beyond the project coordinator to senior clinical localisation leadership or directly to the client's clinical affairs director.

Chapter 19: Data Security and Confidentiality

Pre-clearance medical documentation is commercially sensitive and often subject to regulatory confidentiality obligations, and the client's information-security policy formed a binding part of the engagement terms.

19.1 Access Controls

Document access was restricted to team members actively assigned to a given manual, with access revoked once a document moved out of a team member's assigned workflow stage.

19.2 Secure Transfer and Storage

All documents were transferred through an encrypted file-transfer system and stored on access-controlled infrastructure, with retention and deletion timelines agreed with the client in advance.

19.3 Confidentiality Agreements

Every team member engaged on the project signed a confidentiality agreement specific to the engagement before receiving access to any pre-clearance documentation.

Chapter 20: Training and Professional Development

Sustaining the clinical accuracy standard set out in this report required ongoing investment in the team's clinical knowledge, alongside their linguistic skill.

20.1 Onboarding for New Team Members

Any linguist joining the project completed onboarding covering the master clinical glossary, MOHAP formatting conventions, and the back-translation verification workflow relevant to the document categories they would be assigned.

20.2 Continuing Clinical Education

Lead clinical translators participated in periodic briefings on developments in MOHAP documentation requirements and relevant clinical terminology updates, keeping the team's substantive clinical knowledge current.

20.3 Internal Knowledge Sharing

Recurring back-translation findings and their resolutions were reviewed periodically as a team to surface patterns in safety-critical translation risk across the manual set.

Chapter 21: Comparative Approaches: Device Manuals and Patient-Facing Materials

The client's documentation library spanned both clinician-facing technical manuals and patient-facing information leaflets, each requiring a different register and level of clinical detail despite describing the same underlying products.

21.1 Clinician-Facing Register

Clinical reference manuals and instructions for use retained precise clinical terminology throughout, on the assumption that the reader is a trained healthcare professional able to interpret technical language correctly.

21.2 Patient-Facing Register

Patient information leaflets required the same underlying clinical accuracy but expressed in plain, accessible Arabic appropriate for a general patient audience, without softening or omitting any safety-critical content in the process of simplifying language.

21.3 Maintaining Consistency Across Registers

Where the same dosage or warning information appeared in both clinician-facing and patient-facing documents for the same product, the terminology glossary tracked both the clinical and plain-language rendering side by side, ensuring that simplification for patient readability never introduced a discrepancy in underlying meaning.

Appendix A: Extended Clinical Terminology Glossary

The following glossary reproduces a representative extract of the master clinical terminology reference maintained throughout the project.

Term	Definition
Adverse Event	Rendered per established Arabic pharmacovigilance terminology, distinguished from adverse reaction.
Calibration Interval	Numeric duration terms cross-checked against source figures at every review stage.
Contraindicated Use	Rendered to preserve the exact scope of excluded use-cases stated in the source.
Device Malfunction	Distinguished consistently from user error throughout troubleshooting sections.
Dosage Range	Numeric range terminology verified for consistency between narrative text and dosage tables.
Expiry Date Format	Date format conventions standardised across all packaging and labelling text.
Hazard Symbol	Preserved in internationally recognised form per ISO convention; not translated.
Indication for Use	Rendered per MOHAP-recognised clinical indication terminology.
Off-Label Use	Rendered descriptively where no single established Arabic term existed.
Patient Monitoring Parameter	Rendered consistently across device manuals and clinical reference materials.
Precaution	Distinguished consistently from contraindication throughout all safety sections.
Sterility Assurance Level	Rendered per established Arabic clinical sterilisation terminology.
Storage Condition	Numeric temperature and humidity ranges cross-checked against source figures.
Warning Label	Formatting and terminology standardised across all packaging and device labelling.
Wash-Out Period	Rendered per established Arabic pharmacological terminology.

Appendix B: Back-Translation Verification Checklist

The following checklist summarises the procedural steps applied to safety-critical content before any manual was released for client sign-off and MOHAP submission.

- All dosage figures, warnings and contraindications identified and flagged for back-translation.
- Back-translation completed by a linguist independent of the original translation and review.
- Back-translated text compared against the original English source for any deviation in meaning.
- Any discrepancy escalated for joint review by the translator, independent reviewer and, where necessary, client clinical affairs.
- Numeric consistency confirmed across all instances of the same dosage figure within the full document set.
- Rebuilt diagrams checked against the final verified Arabic text before formatting sign-off.
- Formatting confirmed against MOHAP and applicable emirate-level authority conventions.
- Client clinical affairs sign-off obtained before final release for submission.

Appendix B.1 Common Rejection Causes Avoided

Rejection Cause	How It Was Avoided
Inconsistent dosage terminology	Automated numeric and terminology consistency check
Mismatched diagram and text versions	Diagram version-control system
Non-standard MOHAP terminology	Master clinical glossary aligned to MOHAP standards
Incomplete back-translation coverage	Mandatory back-translation checklist for safety content
Authority-specific formatting errors	Dual-authority formatting templates

Appendix C: Frequently Asked Questions

Question	Answer
Why is back-translation used instead of just a second review?	Back-translation independently verifies meaning without the second linguist being influenced by the first translator's phrasing choices.
Does every sentence in a manual get back-translated?	No; back-translation was applied specifically to safety-critical content such as dosage, warnings and contraindications.
Who has final sign-off on a localised medical manual?	The client's clinical affairs team, following the full internal verification workflow described in this report.
How are diagram changes verified?	Rebuilt diagrams are checked against the final verified Arabic text before formatting sign-off, not approved independently by desktop publishing alone.
What happens if MOHAP or DHA/DOH request a change after submission?	The change is routed back through the full verification workflow, including back-translation if it affects safety-critical content, before resubmission.
Are ISO symbols translated into Arabic?	No; internationally recognised hazard and device symbols are preserved in their standard form, while accompanying explanatory text is localised.

Appendix D: Team Roles and Responsibilities Matrix

Role	Primary Responsibility	Reports To
Clinical Translator	First-draft translation within assigned device category	Project Coordinator
Independent Clinical Reviewer	Clinical accuracy review of safety-critical content	Project Coordinator
Back-Translation Linguist	Independent back-translation of safety-critical passages	Project Coordinator
Desktop Publishing Specialist	Rebuilding diagrams and labelling artwork in Arabic	Project Coordinator
Terminology & Regulatory Coordinator	Glossary maintenance and authority submission tracking	Engagement Lead
Engagement Lead	Overall delivery accountability and risk register ownership	Client Clinical Affairs Director

Appendix D.1 Extended Delivery Timeline

Week	Milestone
Weeks 1-2	Master clinical glossary drafted and approved
Weeks 3-5	Pilot manual localisation and workflow validation
Weeks 6-11	Full manual set localisation (rolling)
Weeks 12-16	Back-translation verification and diagram rebuild
Weeks 17-19	MOHAP submission support
Weeks 20-22	DHA/DOH submission support
Week 26	Post-project review and client feedback session

Appendix E: Illustrative End-to-End Case Narrative

The narrative below walks through a single representative document, a dosage-sensitive patient information leaflet, from intake to final MOHAP clearance, illustrating how the processes described throughout this report operated together in practice.

E.1 Intake and Classification

The leaflet arrived as an 8-page English-language source document describing a dosage-variable consumable product, flagged as safety-critical given its variable dosing table, and assigned to a clinical translator with prior pharmacy translation experience.

E.2 Terminology Alignment and Draft Translation

The terminology coordinator confirmed all dosage-related terms matched the master glossary before translation began. The clinical translator produced a full Arabic draft, preserving the structure of the dosage table exactly.

E.3 Independent Review and Back-Translation

An independent clinical reviewer checked the draft in full, and the dosage table specifically underwent back-translation by a third linguist. The back-translation revealed a single unit discrepancy in one dosage tier, which was corrected before proceeding.

E.4 Desktop Publishing and Final Formatting

The verified Arabic text was rebuilt into the leaflet's layout, including right-to-left restructuring of the dosage table, and checked against the final verified text before formatting sign-off.

E.5 Outcome

The leaflet was cleared by MOHAP on first submission, with the client's clinical affairs team specifically noting the back-translation catch of the dosage unit discrepancy as a clear example of the verification framework functioning as intended.

Appendix F: Glossary of Regulatory Bodies and Abbreviations

Term	Definition
MOHAP	UAE Ministry of Health and Prevention, the federal medical product registration authority.
DHA	Dubai Health Authority, governing healthcare provider distribution in Dubai.
DOH	Department of Health Abu Dhabi, governing healthcare provider distribution in Abu Dhabi.
ISO	International Organization for Standardization, source of internationally recognised device symbols.
IFU	Instructions for Use, the standard technical document accompanying a medical device.

Appendix G: Document Version and Change Control Log

An extract of the version and change-control log used to maintain traceability across the manual set is shown below.

Version	Change Description	Approved By
v1.0	Initial localised manual issued for internal review	Terminology & Regulatory Coordinator
v1.1	Back-translation correction applied to dosage table	Independent Clinical Reviewer
v1.2	Diagram rebuild finalised and checked against verified text	Desktop Publishing Specialist
v2.0	Final version submitted for MOHAP clearance	Engagement Lead

Appendix H: Sample Weekly Status Report Structure

Section	Content
Manuals Completed	List of manuals cleared and delivered in the reporting week
Manuals In Progress	Current workflow stage for each active manual
Back-Translation Findings	Any discrepancies identified and their resolution status
Upcoming Submission Deadlines	MOHAP/DHA/DOH deadlines expected in the following two weeks
Risk Register Updates	Any new or resolved items on the project risk register

Appendix I: Terminology Governance Principles

- Prefer terminology already recognised by MOHAP over a more literal but less officially recognised rendering.
- Distinguish explicitly between clinically distinct concepts, such as contraindication and precaution, or adverse event and adverse reaction.
- Document the reasoning behind every non-obvious terminology decision for regulatory traceability.
- Treat the glossary as authoritative once approved; do not permit informal deviation even for a single document.
- Review and update the glossary whenever MOHAP guidance or clinical terminology conventions change.

Appendix I.1 Governance Review Cycle

The master glossary was formally reviewed at the close of each project phase, with changes approved by the terminology coordinator and communicated to the full clinical translation team before being applied to new documents.

Appendix J: Summary of Key Success Factors

Success Factor	Where Addressed in This Report
Clinical, not purely linguistic, team competence	Chapter 4
Targeted back-translation of safety-critical content	Chapters 6 and 8
Dual-authority formatting discipline	Chapters 2, 12 and Appendix B
Structured clinical query log	Chapters 12 and 13
Diagram version control and technical accuracy checks	Chapters 7 and 9
Continuous team clinical knowledge development	Chapter 20

Taken together, these factors form a repeatable model for delivering safety-critical medical localisation programmes in the UAE at scale.

Acknowledgements

This report reflects the collective work of the clinical translation team, independent reviewers, back-translation linguists, desktop publishing specialists and regulatory coordination staff engaged throughout the programme, together with the ongoing collaboration of the client's clinical and regulatory affairs stakeholders.

References

UAE Ministry of Health and Prevention. Medical product registration and Arabic labelling requirements.

Dubai Health Authority. Documentation conventions for healthcare provider distribution in Dubai.

Department of Health Abu Dhabi. Documentation conventions for healthcare provider distribution in Abu Dhabi.

International Organization for Standardization. Medical device symbol and pictogram conventions referenced in UAE labelling practice.

UAE Ministry of Health and Prevention Pharmacovigilance Guidance. Terminology conventions for adverse event and adverse reaction reporting.

MOHAP Medical Device Registration Directorate. Procedural guidance for localised documentation submission.

Emirates Health Services. Clinical terminology reference materials for UAE healthcare documentation.

UAE Federal Authority for Identity, Citizenship, Customs and Port Security. Import documentation requirements for medical devices.

Gulf Cooperation Council Standardization Organization. Regional medical device labelling harmonisation guidance.

UAE Ministry of Health and Prevention Drug Registration Department. Terminology conventions for pharmaceutical product labelling.

Emirates Authority for Standardization and Metrology. Technical standards referenced in medical device documentation.

Appendix K: Cost and Resource Planning Summary

Accurate resource planning was essential to delivering a safety-critical manual set of this scale within the client's launch timeline. The team developed category-specific effort benchmarks reflecting the added verification burden of safety-critical content, rather than estimating effort on a simple per-word basis.

Appendix K.1 Balancing Dedicated and Flexible Capacity

A core team of clinical translators and independent reviewers was assigned to the project on a dedicated basis to preserve continuity and terminology familiarity, supplemented by a smaller pool of qualified back-translation linguists available for surge demand during the diagram-heavy portion of Phase Two.

Appendix K.2 Budget Transparency with the Client

Resource allocation and associated cost estimates were shared transparently with the client's clinical affairs team at the start of each project phase, with any material deviation flagged and agreed before additional resourcing was committed.

Resourcing Category	Approximate Share of Total Effort
Clinical translation (first draft)	35%
Independent clinical review	20%
Back-translation verification	18%
Desktop publishing and diagram rebuild	17%
Coordination and regulatory liaison	10%

Appendix L: Post-Project Review and Client Feedback

On completion of each project phase, the team conducted a structured review with the client's clinical and regulatory affairs stakeholders to capture feedback and identify improvements for subsequent phases.

Appendix L.1 Feedback Themes

- The back-translation process was repeatedly cited by the client's clinical affairs team as the most valuable safeguard in the engagement.
- The weekly clinical review session was seen as giving the team sufficient visibility to plan downstream regulatory submission work.
- Earlier engagement on right-to-left diagram scoping was identified as an area to strengthen further in future phases.

Appendix L.2 Actions Taken in Response

Following Phase One, the team introduced the dedicated diagram restructuring resource described in Chapter 12 directly in response to client feedback, reducing rework previously required during final formatting sign-off.

Appendix L.3 Client Satisfaction Outcome

The engagement concluded with the client formally retaining the team for ongoing medical localisation support beyond the original product launch, citing the zero-defect safety record and first-submission regulatory clearance as the primary factors behind that decision.

Appendix M: Structure of a Certification and Clearance Statement

Every localised manual submitted for MOHAP, DHA or DOH clearance in this engagement carried an internal certification statement in a consistent structure, summarised below at a structural level.

- Identification of the clinical translator, independent reviewer and back-translation linguist responsible for the document.
- Identification of the source document, including its title, version and product code.
- A statement confirming that all safety-critical content underwent back-translation verification with no unresolved discrepancies.
- The date of internal sign-off and the client clinical affairs approver of record.
- A note of any client-requested amendment incorporated since the previous version.

Appendix M.1 Why Structural Consistency Matters

Regulatory reviewers become familiar with the structure of certification statements they encounter regularly across a manufacturer's submission history, and maintaining a consistent structure across all deliverables was treated as part of the broader formatting discipline described throughout this report.

Appendix N: Notes on Terminology Consistency Across Product Lines

Where the client's four device product lines shared common components or accessories, the terminology glossary was structured to apply shared terminology consistently across product lines rather than maintaining separate, potentially divergent glossaries per product.

Product Line	Shared Terminology Elements	Distinct Elements
Diagnostic Equipment	Calibration, error-code terminology	Device-specific measurement units
Patient Monitoring Devices	Calibration, alarm terminology	Monitoring parameter names
Dosage-Variable Consumables	Dosage and safety terminology	Product-specific dosing tables
General Consumables	Sterility and storage terminology	Product-specific handling instructions

This shared-terminology approach reduced the risk of a clinician encountering inconsistent language when using two related products from the same manufacturer side by side, a scenario common in hospital and clinic settings.

Appendix O: Summary of Key Success Factors

Success Factor	Where Addressed in This Report
Clinical team competence over generalist translation	Chapter 4
Selective, rigorous back-translation of safety content	Chapters 6 and 8
Right-to-left diagram restructuring as a distinct workstream	Chapters 7 and 11
Dual-authority formatting discipline	Chapters 2 and 12
Shared terminology across related product lines	Appendix N
Transparent risk and resource management	Chapters 18, 22 (Appendix K)

Taken together, these factors form a repeatable model for delivering safety-critical medical localisation programmes in the UAE market at scale, consistent with the recommendations set out in Chapter 16.

Appendix P: Sample Escalation Log Entries

The following illustrative extract shows the structure used to log back-translation discrepancies and their resolution, referenced in Chapters 6 and 12, generalised to protect commercially sensitive product details.

Entry	Issue Identified	Resolution
BT-014	Dosage unit discrepancy in back-translation	Corrected following joint clinical review
BT-027	Ambiguous conditional language in warning clause	Escalated to client clinical affairs for clarification
BT-033	Terminology mismatch between IFU and reference manual	Glossary updated and both documents aligned
BT-041	Diagram callout numbering mismatch after rebuild	Diagram corrected and re-verified against text

Maintaining this log in a consistent structure allowed the client's clinical affairs team to review the full history of any discrepancy resolution at a glance, supporting the regulatory traceability expectations described throughout this report.

Appendix Q: Closing Summary Statement

This closing appendix restates, in brief, the central claim of this report: that reliable medical localisation outcomes in the UAE depend on treating clinical accuracy verification as a distinct discipline from general translation quality assurance, resourced and governed accordingly from the outset of any engagement.

The methodology set out across the preceding chapters and appendices, spanning clinical team qualification, targeted back-translation, dual-authority formatting discipline and structured regulatory traceability, is offered as a reusable reference for future medical documentation localisation programmes undertaken for the UAE healthcare market.